{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Desroys du Roure P"],"funding":["Ligue Régionale de l’Herault","Région Occitanie Pyrénées-Méditerranée","Ligue Régionale de la Charente Maritime","Agence Nationale de la Recherche","Inserm Transfert","Université de Montpellier","Ligue Régionale du Gard"],"pagination":["e007135"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10828871"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(1)"],"pubmed_abstract":["Introduction
Triple-negative breast cancer (TNBC) prognosis is poor. Immunotherapies to enhance the antibody-induced natural killer (NK) cell antitumor activity are emerging for TNBC that is frequently immunogenic. The aspartic protease cathepsin D (cath-D), a tumor cell-associated extracellular protein with protumor activity and a poor prognosis marker in TNBC, is a prime target for antibody-based therapy to induce NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC). This study investigated whether Fc-engineered anti-cath-D antibodies trigger ADCC, their impact on antitumor efficacy and tumor-infiltrating NK cells, and their relevance for combinatory therapy in TNBC.Methods
Cath-D expression and localization in TNBC samples were evaluated by western blotting, "],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer."],"pmcid":["PMC10828871"],"funding_grant_id":["N/A","LabEx MabImprove ANR-10-LABX-53-01"],"pubmed_authors":["Mallavialle A","Roger P","Chateau MC","Lajoie L","Ngo G","Guiu S","Chardes T","Villalba M","Desroys du Roure P","Garambois V","Rubio L","Fenou L","Jarlier M","Martineau P","Boissiere-Michot F","David T","Alcaraz LB","Gros L","Liaudet-Coopman E","Mansouri H","Coenon L","Laurent-Matha V"],"additional_accession":[]},"is_claimable":false,"name":"A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.","description":"Introduction
Triple-negative breast cancer (TNBC) prognosis is poor. Immunotherapies to enhance the antibody-induced natural killer (NK) cell antitumor activity are emerging for TNBC that is frequently immunogenic. The aspartic protease cathepsin D (cath-D), a tumor cell-associated extracellular protein with protumor activity and a poor prognosis marker in TNBC, is a prime target for antibody-based therapy to induce NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC). This study investigated whether Fc-engineered anti-cath-D antibodies trigger ADCC, their impact on antitumor efficacy and tumor-infiltrating NK cells, and their relevance for combinatory therapy in TNBC.Methods
Cath-D expression and localization in TNBC samples were evaluated by western blotting, ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jan","modification":"2026-07-14T21:00:13.192Z","creation":"2026-06-24T03:06:49.28Z"},"accession":"S-EPMC10828871","cross_references":{"pubmed":["38290768"],"doi":["10.1136/jitc-2023-007135"]}}